SEC Form 4 · accession 0001562180-17-003515
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Asha Nayak
Director
Period of report
Nov 6, 2017
Accepted (ET)
Nov 8, 2017 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy)F1 | $65.49 | Nov 6, 2017 | A | 20,883 | A | — | Nov 6, 2027 | Common Stock | 20,883 | 20,883 | D |
Explanation of responses
- F1All of the shares subject to the option vest monthly measured from November 6, 2017 (the "Grant Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the Third anniversary of the Grant Date, subject to continued service through such date.